Building the bridge between rhabdomyosarcoma in children, adolescents and young adults: the road ahead

Crit Rev Oncol Hematol. 2012 Jun;82(3):259-79. doi: 10.1016/j.critrevonc.2011.06.005. Epub 2011 Jul 30.

Abstract

Rhabdomyosarcoma (RMS) is a rare type of soft tissue sarcoma that mainly affects children, but also occurs in adolescents and (young) adults (AYA). Despite dramatic survival improvements reported by international study groups in children over the past decades, the awareness of a dismal outcome for older patients with RMS has grown. In contrast to the world-wide organization of care for children with RMS, standard care in adults lags behind. A step forward in RMS management for patients of all ages is urgently needed. Both paediatric oncologists and medical oncologists are essential players in development of a concept of RMS care, but bringing two worlds together seems not so easy. This review provides an overview which highlights the similarities and differences in children and adults with RMS. Furthermore, it comes up with a novel concept to overcome the virtual gap between the treatment approach of children and AYA with RMS.

Publication types

  • Review

MeSH terms

  • Adolescent
  • Age Factors
  • Antineoplastic Agents / administration & dosage*
  • Antineoplastic Agents / therapeutic use
  • Cell Transformation, Neoplastic / genetics
  • Child
  • Child, Preschool
  • Clinical Trials as Topic
  • Female
  • Genetic Predisposition to Disease
  • Humans
  • Infant
  • Male
  • Neoplasm Staging
  • Rhabdomyosarcoma / genetics
  • Rhabdomyosarcoma / mortality
  • Rhabdomyosarcoma / surgery
  • Rhabdomyosarcoma / therapy*
  • Soft Tissue Neoplasms / genetics
  • Soft Tissue Neoplasms / mortality
  • Soft Tissue Neoplasms / surgery
  • Soft Tissue Neoplasms / therapy*
  • Survival Rate
  • Young Adult

Substances

  • Antineoplastic Agents